The Latest Breaking News from AbbVie

Revance is reversing course to stay competitive with AbbVie's aesthetics drug, Botox — and RVNC stock crashed Tuesday in response.

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Drug maker AbbVie reported second-quarter profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose.

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.